

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for July 2025

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Fresenius Kabi Canada Ltd.	Ertapenem for Injection	Invanz	ERTAPENEM	1 g/vial	powder for solution (intravenous, intramuscular)	02496127
Eugia Pharma Inc.	Eugia- Pazopanib	Votrient	PAZOPANIB HYDROCHLORIDE	200 mg	tablet	02552957
Fresenius Kabi Canada Ltd.	Meropenem for Injection, USP	Merrem	MEROPENEM	1 g/vial	IV, powder for solution	02415224
Fresenius Kabi Canada Ltd.	Meropenem for Injection, USP	Merrem	MEROPENEM	500 mg/vial	IV, powder for solution	02415216



Fresenius Kabi Canada Ltd.	Cefazolin for Injection, USP	Ancef	CEFAZOLIN	10 g	IV, powder for solution	02237140
Jamp Pharma Corporation	Jamp Methotrexate Tablets	Methotrexate Tablets, USP	METHOTREXATE	10 mg	tablet	02553740
Sanis Health Inc.	Mirtazapine	Remeron	MIRTAZAPINE	15 mg	tablet	02532689